Raymond James Financial Inc. Invests $3.86 Million in DaVita Inc. (NYSE:DVA)

Raymond James Financial Inc. bought a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 25,836 shares of the company's stock, valued at approximately $3,864,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Invesco Ltd. lifted its holdings in shares of DaVita by 20.9% during the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after purchasing an additional 275,284 shares in the last quarter. Amundi lifted its stake in DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after acquiring an additional 240,126 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of DaVita by 256.8% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock valued at $24,301,000 after acquiring an additional 116,758 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after acquiring an additional 92,014 shares during the period. Finally, California Public Employees Retirement System raised its holdings in shares of DaVita by 75.1% during the fourth quarter. California Public Employees Retirement System now owns 196,788 shares of the company's stock valued at $29,430,000 after purchasing an additional 84,375 shares during the last quarter. Institutional investors own 90.12% of the company's stock.

DaVita Price Performance

Shares of DVA stock traded down $0.89 on Friday, hitting $139.55. 114,580 shares of the stock traded hands, compared to its average volume of 833,582. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 52 week low of $131.27 and a 52 week high of $179.60. The firm has a 50 day simple moving average of $146.09 and a two-hundred day simple moving average of $154.77. The firm has a market cap of $11.16 billion, a price-to-earnings ratio of 13.00, a PEG ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, equities research analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on DVA. StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. Barclays upped their price objective on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Cowen reissued a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, DaVita presently has a consensus rating of "Hold" and a consensus price target of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.